These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 30896751)

  • 1. Hyperprogression-Immunotherapy-Related Phenomenon vs Intrinsic Natural History of Cancer.
    Pearson AT; Sweis RF
    JAMA Oncol; 2019 May; 5(5):743. PubMed ID: 30896751
    [No Abstract]   [Full Text] [Related]  

  • 2. Hyperprogression-Immunotherapy-Related Phenomenon vs Intrinsic Natural History of Cancer-In Reply.
    Ferrara R; Caramella C; Besse B
    JAMA Oncol; 2019 May; 5(5):744. PubMed ID: 30896761
    [No Abstract]   [Full Text] [Related]  

  • 3. Immunotherapy and Hyperprogression: Unwanted Outcomes, Unclear Mechanism.
    Knorr DA; Ravetch JV
    Clin Cancer Res; 2019 Feb; 25(3):904-906. PubMed ID: 30397179
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hyperprogression during immunotherapy: do we really want to know?
    Champiat S; Besse B; Marabelle A
    Ann Oncol; 2019 Jul; 30(7):1028-1031. PubMed ID: 31173063
    [No Abstract]   [Full Text] [Related]  

  • 5. Family history of cancer and DNA damage response genes: Two sides of the same coin?
    Cortellini A; Bersanelli M; Ficorella C; Buti S
    Thorac Cancer; 2019 Feb; 10(2):401. PubMed ID: 30536563
    [No Abstract]   [Full Text] [Related]  

  • 6. [Current challenges with PD-L1 testing for immunotherapy biomarkers in non-small cell lung cancer].
    Li Y; Chen J
    Zhonghua Bing Li Xue Za Zhi; 2019 Aug; 48(8):585-589. PubMed ID: 31422587
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Predictive biomarkers for immune checkpoint inhibitors in non-small-cell lung cancer].
    Fu MJ; Zhou JY
    Zhonghua Jie He He Hu Xi Za Zhi; 2020 Feb; 43(2):87-91. PubMed ID: 32062877
    [TBL] [Abstract][Full Text] [Related]  

  • 8. There and back again: An immunotherapy tale.
    Guo Y; Krupnick AS
    J Thorac Cardiovasc Surg; 2018 Apr; 155(4):1771-1774. PubMed ID: 29409610
    [No Abstract]   [Full Text] [Related]  

  • 9. DNA damage response signaling as a predictive biomarker and synergistic therapeutic target for anti-PD-1/PD-L1 immunotherapy in non-small cell lung cancer.
    Zhu Z; Chen P; Yan Z
    Thorac Cancer; 2018 Aug; 9(8):901-903. PubMed ID: 29932513
    [No Abstract]   [Full Text] [Related]  

  • 10. Implications of Programmed Cell Death 1 Ligand 1 Heterogeneity in the Selection of Patients With Non-Small Cell Lung Cancer to Receive Immunotherapy.
    Mansfield AS; Dong H
    Clin Pharmacol Ther; 2016 Sep; 100(3):220-2. PubMed ID: 26916808
    [TBL] [Abstract][Full Text] [Related]  

  • 11. KEYNOTE-024: Unlocking a pathway to lung cancer cure?
    Rusch VW; Chaft J; Hellmann M
    J Thorac Cardiovasc Surg; 2018 Apr; 155(4):1777-1780. PubMed ID: 29395215
    [No Abstract]   [Full Text] [Related]  

  • 12. Monitoring immunotherapy outcomes with circulating tumor DNA.
    Goldberg SB; Patel AA
    Immunotherapy; 2018 Sep; 10(12):1023-1025. PubMed ID: 30185140
    [No Abstract]   [Full Text] [Related]  

  • 13. Characterization of Hyperprogression After Immunotherapy in a Lung Adenocarcinoma Patient With Strong Expression of Programmed Death Ligand 1.
    Peng Y; Zhang L; Zeng T; Liu L; Liu X; Yang Y; Zhang H; Ruan Z
    J Thorac Oncol; 2020 Jan; 15(1):e4-e8. PubMed ID: 31864557
    [No Abstract]   [Full Text] [Related]  

  • 14. Programmed death of chemotherapy in non-small-cell lung cancer?
    Leduc C; Quoix E
    Lancet; 2017 Jan; 389(10066):227-228. PubMed ID: 27979385
    [No Abstract]   [Full Text] [Related]  

  • 15. Pseudoprogression and Immune-Related Response in Solid Tumors.
    Chiou VL; Burotto M
    J Clin Oncol; 2015 Nov; 33(31):3541-3. PubMed ID: 26261262
    [No Abstract]   [Full Text] [Related]  

  • 16. The Significance of the PD-L1 Expression in Non-Small-Cell Lung Cancer: Trenchant Double Swords as Predictive and Prognostic Markers.
    Takada K; Toyokawa G; Shoji F; Okamoto T; Maehara Y
    Clin Lung Cancer; 2018 Mar; 19(2):120-129. PubMed ID: 29153898
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Moving Programmed Death-1 Inhibitors to the Front Lines in Non-Small-Cell Lung Cancer.
    Gainor JF
    J Clin Oncol; 2016 Sep; 34(25):2953-5. PubMed ID: 27382094
    [No Abstract]   [Full Text] [Related]  

  • 18. [The predicive biomarkers of programmed death receptor-l/ligand antibodes in the treatement of non-small-cell lung cancer].
    Xu Y; Bai L
    Zhonghua Jie He He Hu Xi Za Zhi; 2018 Oct; 41(10):799-803. PubMed ID: 30347553
    [No Abstract]   [Full Text] [Related]  

  • 19. Supportive care in the era of immunotherapies for advanced non-small-cell lung cancer.
    Awada G; Klastersky J
    Curr Opin Oncol; 2018 Mar; 30(2):98-104. PubMed ID: 29303787
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incidence of Pneumonitis With Use of Programmed Death 1 and Programmed Death-Ligand 1 Inhibitors in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis of Trials.
    Khunger M; Rakshit S; Pasupuleti V; Hernandez AV; Mazzone P; Stevenson J; Pennell NA; Velcheti V
    Chest; 2017 Aug; 152(2):271-281. PubMed ID: 28499515
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.